Vera Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

Ticker: VERA · Form: 10-K · Filed: Mar 27, 2024 · CIK: 1831828

Vera Therapeutics, INC. 10-K Filing Summary
FieldDetail
CompanyVera Therapeutics, INC. (VERA)
Form Type10-K
Filed DateMar 27, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $16.05, $49.2 billion, $6.0 billion, $10.0 billion
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Vera Therapeutics, Financial Report, Biopharmaceutical, SEC Filing

TL;DR

<b>Vera Therapeutics, Inc. has filed its 2023 10-K report detailing its financial performance and business operations.</b>

AI Summary

Vera Therapeutics, Inc. (VERA) filed a Annual Report (10-K) with the SEC on March 27, 2024. Vera Therapeutics, Inc. filed its 2023 Form 10-K on March 27, 2024, reporting on its fiscal year ending December 31, 2023. The filing details the company's business, financial condition, and results of operations for the fiscal year 2023. Key financial data and disclosures related to equity incentive plans, common stock, and debt facilities are included. The report covers various financial instruments and fair value measurements, including money market funds and corporate debt securities. It also references specific dates related to equity issuances and agreements, such as the IPO on October 31, 2020.

Why It Matters

For investors and stakeholders tracking Vera Therapeutics, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Vera Therapeutics' financial health and strategic positioning for the fiscal year 2023, crucial for investors assessing the company's performance and future prospects. The detailed disclosures on equity, debt, and financial instruments offer insights into the company's capital structure and risk management strategies, important for understanding its operational stability.

Risk Assessment

Risk Level: medium — Vera Therapeutics, Inc. shows moderate risk based on this filing. The company operates in the pharmaceutical industry, which is subject to significant regulatory hurdles, lengthy development cycles, and intense competition, as detailed in the 10-K filing.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Vera Therapeutics' operational performance and potential challenges in the biopharmaceutical sector.

Key Numbers

Key Players & Entities

FAQ

When did Vera Therapeutics, Inc. file this 10-K?

Vera Therapeutics, Inc. filed this Annual Report (10-K) with the SEC on March 27, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Vera Therapeutics, Inc. (VERA).

Where can I read the original 10-K filing from Vera Therapeutics, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Vera Therapeutics, Inc..

What are the key takeaways from Vera Therapeutics, Inc.'s 10-K?

Vera Therapeutics, Inc. filed this 10-K on March 27, 2024. Key takeaways: Vera Therapeutics, Inc. filed its 2023 Form 10-K on March 27, 2024, reporting on its fiscal year ending December 31, 2023.. The filing details the company's business, financial condition, and results of operations for the fiscal year 2023.. Key financial data and disclosures related to equity incentive plans, common stock, and debt facilities are included..

Is Vera Therapeutics, Inc. a risky investment based on this filing?

Based on this 10-K, Vera Therapeutics, Inc. presents a moderate-risk profile. The company operates in the pharmaceutical industry, which is subject to significant regulatory hurdles, lengthy development cycles, and intense competition, as detailed in the 10-K filing.

What should investors do after reading Vera Therapeutics, Inc.'s 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to understand Vera Therapeutics' operational performance and potential challenges in the biopharmaceutical sector. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Filing Stats: 4,472 words · 18 min read · ~15 pages · Grade level 16.6 · Accepted 2024-03-26 20:35:25

Key Financial Figures

Filing Documents

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 44 Item 1B. Unresolved Staff Comments 95 Item IC. Cybersecurity 95 Item 2.

Properties

Properties 96 Item 3.

Legal Proceedings

Legal Proceedings 96 Item 4. Mine Safety Disclosures 96 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 97 Item 6. Reserved 97 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 98 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 105 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 105 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 127 Item 9A.

Controls and Procedures

Controls and Procedures 127 Item 9B. Other Information 127 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 128 PART III Item 10. Directors, Executive Officers and Corporate Governance 129 Item 11.

Executive Compensation

Executive Compensation 129 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 129 Item 13. Certain Relationships and Related Transactions, and Director Independence 129 Item 14. Principal Accountant Fees and Services 129 PART IV Item 15. Exhibit and Financial Statement Schedules 130 Item 16. Form 10-K Summary 130 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (the Annual Report) may contain "forward-looking statements" within the meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under Part I, Item 1A, "Risk Factors" in this Annual Report. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent our current expectations or beliefs concerning various future events, may contain words such as "may," "will," "expect," "anticipate," "intend," "plan," "believe," "estimate" or other words indicating future results, though not all forward-looking statements necessarily contain these identifying words. Such statements may include, but are not limited to, statements concerning the following: our financial performance; the sufficiency of our existing cash to fund our future operating expenses and capital expenditure requirements; the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; the scope, progress, results and costs of developing our product candidates and conducting nonclinical studies and clinical trials; the timing and costs involved in obtaining and maintaining regulatory approval of our product candidates and the timing

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing